Examination of effect and safety of short acting beta2 agonist in stability period COPD patient(Acute effect and chronic effect)

Examination of effect and safety of short acting beta2 agonist in stability period COPD patient(Acute effect and chronic effect) - Examination of effect and safety of short acting beta2 agonist in stability period COPD patient(-Acute effect and chronic effect)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005101

Enrollment

Registered

2011-02-17

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

short acting beta2 agonist placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.It is COPD patient of a possible outpatient care in the this hospital. 2.The severity of symptoms : from the middle syndrome to the serious illness in the GOLD guideline. 3.The age is 85 years old from 40 years old.

Exclusion criteria

Exclusion criteria: 1.Amalgamation of bronchitic asthma 2.When the beta2 stimulation medicine is a taboo 3.Additionally, person who seems to be improper examination doctor in charge it

Design outcomes

Primary

Measure	Time frame
St.George' s Respiratory Questionnaire	—

Countries

Japan

Contacts

Public ContactMayumi Nihei

TOHOKU ROSAI HOSPITAL Respiratory

022-275-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026